Background: In patients with ST-elevation myocardial infarction (STEMI), C-reactive protein (CRP) levels are associated with larger infarct size, transmural extent, and poor function of left ventricle and independently predict 30-day mortality. CRP-apheresis following STEMI showed to be feasible, safe, and has significant beneficial effect both on myocardial infarction size and wall motion. To the best of our knowledge, this is only the second published clinical evaluation of the efficacy and safety of selective CRP-apheresis in the STEMI treatment using Spectra-Optia and Pentrasorb CRP-adsorber systems. Case Report: A 53-year-old female was referred with anterior STEMI. After percutaneous coronary intervention, patient received standard post-STEMI therapy according to current guidelines. Selective therapeutic plasma exchange (TPE) was performed using Spectra-Optia (Terumo BCT; USA) and Pentrasorb CRP-adsorber (Pentracor GmbH; Germany) systems. Antecubital veins were used for vascular access and acid-citrate-dextrose solution (ACD formula A; total volume = 1,026 mL) was utilized as anticoagulant. The volume of processed blood was 15,600 mL. The removed “natural” plasma (total volume = 8,329 mL) was replaced with CRP-depleted autologous plasma (total volume = 8,085 mL). This intensive TPE-treatment was well tolerated, without adverse effects, or complications. The CRP plasma levels were: initial = 4.2 mg/L 6 h after acute myocardial infarction (AMI), pre-apheresis = 16.4 mg/L, and post-apheresis = 4.59 mg/L (CRP-depletion = 72%). There were neither significant changes observed in biochemistry nor any alterations in plasma hemostatic activity investigated before and after CRP-adsorption performed. Conclusion: Early performed CRP-apheresis is a promising innovative therapeutic approach for STEMI treatment that could provide a reduced size of infarction zone – with inferior occurrence of heart failure after AMI. However, precise and complete evaluation of the efficacy and safety of this treatment requires further multicenter randomized and larger clinical studies.

Keywords:
Myocardial infarction, C-reactive protein apheresis, Selective plasma exchange
1.
Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.
J Exp Med
. 1999 Dec;190(12):1733–40.
2.
Ørn S, Manhenke C, Ueland T, Damås JK, Mollnes TE, Edvardsen T, et al. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction.
Eur Heart J
. 2009 May;30(10):1180–6.
3.
Morariu M, Márton E, Mester A, Rațiu M, Benedek I. Association between Acute Inflammatory Response and Infarct Size in STEMI Patients Undergoing Primary PCI.
J Cardiovasc Emerg
. 2018;4(3):140–6.
4.
Garlichs C, Torzewski J, Sheriff AC, Pfluecke C, Darius H, Lehrke S, et al. Results from the CAMI1 Study: selective CRP-apheresis as a new treatment option in acute myocardial infarction ESC Congress 2019 together with World Congress of Cardiology 31 August – 4 September 2019, Paris – France.
5.
Ries W, Sheriff A, Heigl F, Zimmermann O, Garlichs CD, Torzewski J. “First in Man”: Case Report of Selective C-Reactive Protein Apheresis in a Patient with Acute ST Segment Elevation Myocardial Infarction.
Case Rep Cardiol
. 2018 Nov;2018:4767105.
6.
Ries W, Heigl F, Garlichs C, Sheriff A, Torzewski J. Selective C-Reactive Protein-Apheresis in Patients.
Ther Apher Dial
. 2019 Dec;23(6):570–4.
7.
Balint B, Pavlovic M, Jevtic M, Hrvacevic R, Ignjatovic L, Ostojic G, et al. Simple “closed-circuit” group-specific immunoadsorption system for ABO-incompatible kidney transplants.
Transfus Apheresis Sci
. 2007 Jun;36(3):225–33.
8.
Balint B, Stepic N, Todorovic M, Zolotarevski L, Ostojic G, Vucetic D, et al. Ibuprofen-induced extensive toxic epidermal necrolysis - a multidisciplinary therapeutic approach in a single case.
Blood Transfus
. 2014 Jul;12(3):438–9.
9.
Stumpf C, Sheriff A, Zimmermann S, Schaefauer L, Schlundt C, Raaz D, et al. C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty.
Arch Med Sci
. 2017 Aug;13(5):1086–93.
10.
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
N Engl J Med
. 2004 Apr;350(14):1387–97.
11.
Slagman AC, Bock C, Abdel-Aty H, Vogt B, Gebauer F, Janelt G, et al. Specific removal of C-reactive protein by apheresis in a porcine cardiac infarction model.
Blood Purif
. 2011;31(1-3):9–17.
12.
Sheriff A, Schindler R, Vogt B, Abdel-Aty H, Unger JK, Bock C, et al. Selective apheresis of C-reactive protein: a new therapeutic option in myocardial infarction?
J Clin Apher
. 2015 Feb;30(1):15–21.
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.